James K. McCloskey II, MD

Articles

Evolving Treatment Landscape of Myelofibrosis

August 29th 2023

Closing out their discussion on myelofibrosis management, experts from the John Theurer Cancer Center consider novel therapies under investigation and the future treatment paradigm.

Factors Informing Selection and Use of JAK Inhibitors in Myelofibrosis

August 22nd 2023

Panelists consider the patient and disease factors that might indicate use of a specific JAK inhibitor when managing patients with myelofibrosis.

Optimal Selection and Sequencing of Therapy in Patients With Myelofibrosis

August 22nd 2023

Broader perspectives on the optimal selection and sequencing of systemic therapy in patients diagnosed with myelofibrosis.

Molecular Markers and Subsets of Myelofibrosis

July 25th 2023

Expert panelists consider key molecular markers that guide the classification and management of myelofibrosis, along with other important subsets of disease.

Dr. McCloskey on the Results of the ASCERTAIN Trial in MDS

January 8th 2020

James K. McCloskey II, MD, discusses the results of the phase III ASCERTAIN trial in myelodysplastic syndrome.

Dr. McCloskey Discusses IDH Inhibitors in AML

February 14th 2018

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses IDH inhibitors in acute lymphoblastic leukemia (AML).

Dr. McCloskey Discusses Targeting CD19 in B-Cell ALL

December 22nd 2017

James K. McCloskey II, MD, medical oncologist, Division of Leukemia and the Adult Blood and Marrow Stem Cell Transplantation Program, John Theurer Cancer Center, discusses targeting CD19 in patients with acute lymphocytic leukemia.

Pacritinib May Offer New Option for Tackling Myelofibrosis in Patients With Cytopenias

February 3rd 2016

Pacritinib, a JAK2/FLT3 inhibitor, is among the most promising of those emerging options for patients with myelofibrosis.